Lars Rasmussen, BSc Engineering and MBA, was born on 31 March 1959 and is a Danish citizen. He was nominated for election to Lundbeck's Board of Directors at the 2013 annual general meeting. He chairs Lundbeck’s Remuneration and Scientific Committees, and is member of Lundbeck's Audit Committee.
Lars Rasmussen has considerable management experience in global med-tech. Lars Rasmussen was appointed as CEO of Coloplast A/S in 2008 and has been member of the company's executive management since 2001. In this period, he has been responsible for various functions in the group, including global sales, innovation and production. He has performed these duties from both Denmark and the USA.
Lars Rasmussen's special qualifications for serving on Lundbeck's Board of Directors include his top management experience and knowledge of efficiency improvements and internationalisation.
Lars Rasmussen is member of the Board of Directors of William Demant Holding A/S
Lene Skole, BCom Finance, was born on 28 April 1959 and is a Danish citizen. She was nominated for election to Lundbeck’s Board of Directors at the 2015 annual general meeting. She is member of Lundbeck's Remuneration and Scientific Committees.
Lene Skole is CEO at the Lundbeck Foundation. Prior to joining the Lundbeck Foundation in 2014, Lene Skole was CFO at Coloplast A/S where she was a member of the company’s executive management since joining in 2005. Lene Skole’s responsibilities included finance, IT, HR, communication, strategy and M&A. Before 2005, Lene Skole held various positions in the AP Moller-Maersk group most recently as CFO of Maersk Company Ltd., London from 2000-2005.
Lene Skole’s special qualifications for serving on Lundbeck’s Board of Directors include extensive knowledge and expertise within financing, strategy, business development and M&A as well as management experience from international companies including med-tech.
Lene Skole is vice chairman of the Board of Directors of DONG Energy A/S, Falck A/S, ALK-Abelló A/S, and member of the Board of Directors of Tryg A/S and Tryg Forsikring A/S.
Jesper Ovesen, MSc in finance and state authorized public accountant, was born on 20 March 1957 and is a Danish citizen. He was nominated for election to Lundbeck’s Board of Directors at the 2015 annual general meeting and chairs Lundbeck’s Audit Committee.
Jesper Ovesen most recently held the position of executive chairman of the Board of Directors of Nokia Siemens Networks BV. Prior to this, he served as CFO in TDC A/S, Lego A/S and Danske Bank A/S, and finance director at Novo Nordisk A/S.
Jesper Ovesen’s special qualifications for serving on Lundbeck’s Board of Directors include his international management experience and his expertise in finance, accounting and international capital markets.
Jesper Ovesen is vice chairman of the Board of Directors of Scandinaviska Enskilda Banken AB and member of the Board of Directors of Sunrise Communications Group AG and ConvaTec Group PLC
Lars Holmqvist, MSc in business administration, was born on 4 September 1959 and is a Swedish citizen. He was nominated for election to Lundbeck’s Board of Directors at the 2015 annual general meeting. He is member of Lundbeck’s Audit Committee.
Lars Holmqvist is senior advisor within healthcare at Bain Capital. He previously served as vice president responsible for sales and marketing at Pharmacia. In addition he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Group, DAKO and Agilent Technologies.
Lars Holmqvist’s special qualifications for serving on Lundbeck`s Board of Directors include his international management experience, his expertise in finance, and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry.
Lars Holmqvist is member of the Board of Directors of the Lundbeck Foundation, ALK-Abelló A/S, Tecan AG and BPL Ltd.
Jeremy M. Levin, BA Zoology, MA and DPhil in Molecular Biology and MB BChir Medicine and Surgery, was born on 9 September 1953 and is a British and US citizen. He was elected to Lundbeck's board of Directors at the 2017 annual general meeting. Jeremy M. Levin has more than 25 years of experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide.
Since 2014, he has been CEO and chairman of Ovid Therapeutics, a New York-based neurology company focused on rare and orphan diseases of the brain. Previously, Jeremy M. Levin served as President & CEO of Teva Pharmaceuticals and before becoming CEO of Teva, he was a member of the Executive Committee of Bristol-Myers Squibb where he was globally responsible for overall strategy, alliances and business development. Prior to that, he was Global Head of Strategic Alliances at Novartis, where he established and managed strategic collaborations with multiple companies and research institutions around the world.
Jeremy M. Levin’s special qualifications for serving on Lundbeck’s Board of Directors include a robust blend of clinical insight and experience, business development skills, corporate strategy and financial savvy. In addition he has substantial board experience.
Jeremy M. Levin is member of the Board of Directors of BioCon in India, ZappRx and on the Board and Executive Committee of BIO, the Biotechnology Innovation Organization in the USA.
Mona Elisabeth Elster has been employed with Lundbeck since 1994. She works in Discovery Chemistry & DMPK and was appointed Senior Lab Technician in 2009.
Mona Elisabeth Elster finished her Lab Technician education in 1984 and received a Marketing Diploma in 1989. She has previously worked with the Carlsberg Research Center, the Royal Veterinary and Agricultural University in Denmark, the Faculty of Pharmaceutical Sciences under the University of Copenhagen, and Danisco.
Since 1995, Mona Elisabeth Elster has been a member of the board of Lundbeck's salaried employees' association, where she was appointed chairman in 2002.
Jørn Mayntzhusen has been with Lundbeck since 2002 currently being Senior Manager for Supply Optimisation and Launches of new products. Previously Jørn Mayntzhusen has been responsible for Production Planning and Costing, as well as head of Customer Supply.
Originally educated as a banker in 1988 he has obtained a BSc in Logistics (HD(L)) at Copenhagen Business School in 1995 and a Master of Business Administration (MBA) from Edinburgh Business School in 2002.
Jørn Mayntzhusen started working with Handelsbanken 1986-1990 followed by 2 years at Thule Air Base with Greenland Contractors 1990-1992. In 1992 he started studying for his BSc and was employed as Logistic Assistant with Braun Nordic 1993-1997. For the next 2 years Jørn Mayntzhusen worked as Business Management Advisor with Mellemfolkeligt Samvirke in Zimbabwe. Prior to working for Lundbeck Jørn was Nordic Logistic Manager with Moulinex Krups 1999-2002.
Henrik Sindal Jensen, Ph.D. (Neuroscience) has been employed with Lundbeck since 2004. Currently, Henrik holds a position as Principal Scientist in Research acting as project manager and scientist involved in a number of Lundbeck’s preclinical research projects. In Research, Henrik has held a number of different positions including line management.
Henrik holds degrees in Molecular Biology (M.Sc.) and Chemistry (B.Sc) from the University of Aarhus and earned his industrial Ph.D. degree in collaboration between the Graduate School of Neuroscience at the University of Copenhagen and NeuroSearch. Prior to joining Lundbeck, Henrik held positions as Assistant Professor at the Department of Medical Physiology, University of Copenhagen and as Research Assistant at the Department of Molecular and Structural Biology, University of Aarhus.